Health
Johnson & Johnson COVID-19 Vaccine Candidate Demonstrates Robust Protection in Pre-Clinical Studies – HospiMedica
Johnson & Johnson’s (New Brunswick, NJ, USA) lead vaccine candidate has successfully protected monkeys against infection with SARS-CoV-2, the virus that causes COVID-19, in pre-clinical studies.
Johnson & Johnsons (New Brunswick, NJ, USA) lead vaccine candidate has successfully protected monkeys against infection with SARS-CoV-2, the virus that causes COVID-19, in pre-clinical studies.The companys investigational adenovirus serotype 26 (Ad26) vector-based vaccine elicited a robust immune response as demonstrated by neutralizing antibodies, successfully preventing subsequent infection and providing complete or near-complete protection in the lungs from the virus in non-human primates…
-
General23 hours agoPolice say new leads being pursued after baby’s body found in Alexander Heights stormwater drain
-
Noosa News9 hours agoMan dies in Brisbane crash, women and girl rushed to hospital
-
Noosa News23 hours agoPolice charge second man over alleged assault in Gold Coast car seller on Facebook’s Marketplace
-
General23 hours agoRecord Qantas fine reveals Australia’s perverse moral compass